Seno wraps up study for Imagio optoacoustic breast system

By staff writers

September 29, 2015 -- Optoacoustic breast imaging developer Seno Medical Instruments has finished the final phase of a pivotal study to evaluate its Imagio breast imaging system.

Seno's PIONEER study, officially titled A Pivotal Study of Imaging With Optoacoustics to Diagnose Breast Masses Detected by Mammography and/or Diagnostic Ultrasound, enrolled more than 2,100 subjects at 16 U.S. institutions. The study was designed to demonstrate that Imagio can provide physicians with vital information needed to determine whether a suspicious breast mass is cancerous or not, helping to avoid negative biopsy procedures, Seno said. PIONEER compared the sensitivity and specificity of Imagio with grayscale ultrasound for breast lesions.

Pilot results from the study will be presented at the upcoming RSNA 2015 meeting in Chicago, and the study will be used as the basis for a premarket approval application (PMA) with the U.S. Food and Drug Administration (FDA), Seno said.

The company also noted that results from a separate European postmarketing and clinical follow-up study, called MAESTRO, or "Imaging With Optoacoustics to Downgrade BI-RADS Classification Relative to Other Diagnostic Methodologies," will be presented at this week's European Society of Breast Imaging (EUSOBI) annual scientific meeting in London. Five sites from the Netherlands are currently participating in that study.

Seno touts reader study ruling out breast cancer
Seno Medical Instruments released study results indicating that its Seno Imagio breast imaging system improves physicians' ability to rule out breast...
Seno wraps up enrollment for Imagio trial
Optoacoustic imaging developer Seno Medical Instruments said it has finished enrolling patients in a study of its Imagio breast imaging system.
Seno enrolls 100 patients in breast cancer study
Optoacoustic imaging developer Seno Medical Instruments has enrolled the first 100 patients in a study of its Imagio imaging system.
Seno Medical taps Stavros as medical director
Optoacoustic imaging developer Seno Medical Instruments has named Dr. Thomas Stavros as its medical director.
Seno nets funding for breast imaging technology
Seno Medical Instruments has received more than $3 million to launch commercial operations to further develop its patented laser optoacoustic breast...

Copyright © 2015

Last Updated np 12/21/2015 12:02:31 PM